MYND LIFE SCIENCS INC - MYNDF STOCK NEWS

MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) announced a proposed issuance of 4 million shares at $0.71 per share to eliminate $3.5 million in debt, including an outstanding debenture. The debenture was originally issued to support the company's development of a diagnostic biomarker for major depressive disorder (MDD), Phase 2B Alzheimer's trial, and IL-33 biomarker for cancer monitoring. The company is now focusing solely on developing the MDD diagnostic biomarker. The new shares will be subject to a four-month hold period from issuance, pending regulatory approval.

MYND Life Sciences welcomes Ms. Laurie Bakke to the Board, and announces a proposed merger with Cava Healthcare Inc. The strategic merger aims to redefine medical innovation and develop new treatment options for Alzheimer's disease, depression, and cancer. MYND continues to focus on repurposing FDA approved anti-angiogenesis cancer drugs for Alzheimer's treatment, developing a diagnostic biomarker for depression, and advancing the development of an immune-regulator for cancer monitoring and prognosis.

MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) appoints Mr. John Campbell as President and CEO. Campbell's financial expertise and strategic proficiency are expected to drive MYND's commercialization of intellectual property in neuro pharmaceutical treatments and diagnostic tools for inflammatory and neurological diseases.

MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) announces the appointment of Dr. Lyle Oberg as the Board Chair of Alberta Health Services. Dr. Oberg, the current CEO and Director of Mynd, brings a distinguished career in public service and private practice. With an annual budget of $16.5 billion and approximately 125,000 employees, Alberta Health Services is one of Canada's most significant organizations. Dr. Oberg's transition to Executive Chairman will allow him to focus on shaping the company's future and guiding strategic initiatives, partnerships, and acquisitions.

MYND Life Sciences and Cava Healthcare Inc announce a potential merger to create a new industry leader in biopharmaceutical research and development. The merger is expected to redefine medical innovation and drive transformative advancements in healthcare.

MYND Life Sciences has not made its payment obligations under its unsecured convertible debentures, leading to ongoing discussions with bondholders regarding potential amendments and extension of the Maturity Date. The company has formed a special committee to evaluate alternatives and communicate with bondholders within 30 days.

MYND Life Sciences announces the revocation of its Management Cease Trade Order after filing necessary financial statements.

MYND Diagnostics has announced its involvement in a $3 million clinical trial funded by the Government of Australia, aimed at evaluating psilocybin-assisted psychotherapy for treatment-resistant depression. The trial will employ MYND's proprietary biomarkers to monitor patient responses and progress. Conducted by Dr. Paul Fitzgerald at Monash University, this phase 2b trial could lead to a multi-site phase 3 trial within a year, paving the way for potential regulatory approval by the Therapeutic Goods Association. MYND also anticipates entering more clinical trials in 2022/2023 to advance its biomarker development.

MYND Life Sciences Inc. has entered a Collaborative Research Agreement with the University of British Columbia to explore novel therapies for neurological diseases. The focus is on developing precision medicines, particularly those involving Psilocybins, aimed at improving treatment outcomes for conditions like dementia.

MYND is advancing various clinical programs, including a pivotal trial for novel biomarkers for treatment-resistant depression, with plans for additional clinical trials in 2022/2023. The company also announced the departure of COO Jordan Cleland, with Dr. Chahaat Singh assuming operational responsibilities.